Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cumulative dose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    780 result(s) found for: Cumulative dose. Displaying page 9 of 39.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2016-001179-60 Sponsor Protocol Number: CABASTY Start Date*: 2019-10-21
    Sponsor Name:A.R.T.I.C (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie)
    Full Title: Randomized multicenter, phase III trial evaluating the safety of 2 schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (≥ 70 years) with metastatic castration-resi...
    Medical condition: Metastatic castration-resistant prostate cancer (mCRPC)
    Disease:
    Population Age: Elderly Gender: Male
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002188-23 Sponsor Protocol Number: KLOPOXID2021 Start Date*: 2021-12-01
    Sponsor Name:Bispebjerg Hospital
    Full Title: Association between variations in CYP pheno- and genotypes and plasma concentration of chlordiazepoxide in the treatment of alcohol withdrawal symptoms
    Medical condition: Alcohol withdrawal symptomps
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10001637 Alcoholic withdrawal symptoms LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005067-52 Sponsor Protocol Number: DPCG-01 Start Date*: 2022-02-10
    Sponsor Name:Aalborg University Hospital, Department of Oncology
    Full Title: A randomized phase II study of gemcitabine versus reduced-dose combination chemotherapy in fragile patients with non-resectable pancreatic cancer.
    Medical condition: Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002082-19 Sponsor Protocol Number: LAQ-MS-306 Start Date*: 2013-11-25
    Sponsor Name:Teva Pharmaceutical Industries, Ltd.
    Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of...
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SE (Prematurely Ended) FI (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003274-22 Sponsor Protocol Number: 22093 Start Date*: 2022-10-25
    Sponsor Name:Bayer HealthCare LLC
    Full Title: A Randomized, Double-Blind, Single-Dose, Parallel, Placebo-Controlled Pivotal Trial to Confirm the Efficacy of a Fixed Dose Combination Tablet of Naproxen Sodium and Caffeine to Effectively Allevia...
    Medical condition: Postoperative dental pain
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10054711 Postoperative pain LLT
    20.0 100000004856 10059723 Tooth pain LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023048-34 Sponsor Protocol Number: NT-KO-003-2010-01 Start Date*: 2011-04-28
    Sponsor Name:NEUROTEC PHARMA, S.L
    Full Title: Ensayo Clínico Fase IIa, Multicéntrico, Doble Ciego para Evaluar la Eficacia y Seguridad de dosis bajas de Diazoxida oral en el tratamiento de la Esclerosis Múltiple
    Medical condition: Tratamiento de la Esclerosis Múltiple.
    Disease: Version SOC Term Classification Code Term Level
    13 10063399 Esclerosis múltiple remitente-recurrente LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004519-43 Sponsor Protocol Number: NN18344 Start Date*: 2005-01-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003389-42 Sponsor Protocol Number: DASA-PEGIFN Start Date*: 2013-06-26
    Sponsor Name:CHU DE POITIERS
    Full Title: A phase II study to assess the efficacy and safety of frontline combination of dasatinib (SPRYCEL®) and pegylated-interferon alpha 2b (Peg-IFNα2b) therapy in patients newly diagnosed with chronic p...
    Medical condition: Patients with newly diagnosed chronic phase Chronic Myeloid Leukemia (CP-CML), not previously treated with Tyrosine Kinase Inhibitors (TKIs). First line therapy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001044-54 Sponsor Protocol Number: Bosupeg Start Date*: 2018-10-04
    Sponsor Name:St Olavs Hospital -Trondheim University Hospital
    Full Title: A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS: A RANDOMIZED PROSPECTIVE TRIAL
    Medical condition: Chronic myeloid leukemia at diagnosis-chronich phase
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004230-42 Sponsor Protocol Number: 18562 Start Date*: 2020-07-31
    Sponsor Name:Radboudumc
    Full Title: Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio study
    Medical condition: psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037155 Psoriasis and similar disorders LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014870-16 Sponsor Protocol Number: BA2009-28-01 Start Date*: 2009-12-10
    Sponsor Name:BioAlliance Pharma
    Full Title: A phase II, multicentre, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of Clonidine Lauriad® 50 μg and 100 μg mucoadhesive buccal tablet (MBT) applied once da...
    Medical condition: Prevention and treatment of chemoradion therapy-induced oral mucositis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-000421-39 Sponsor Protocol Number: AMLSG26-16/AML-ViVA Start Date*: 2017-02-03
    Sponsor Name:University Hospital Regensburg represented by Kaufmännischer Direktor
    Full Title: Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >=60 years with acute myelo...
    Medical condition: acute myeloid leukemia refractory to standard induction chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002622-24 Sponsor Protocol Number: CAIN457R1DE01 Start Date*: 2022-06-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, parallel-group, double-blind, placebo-controlled, multicenter trial to investigate the efficacy and safety of subcutaneously administered secukinumab in patients with new-onset of gia...
    Medical condition: Giant Cell Arteritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10047065 - Vascular disorders 10018250 Giant cell arteritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002919-18 Sponsor Protocol Number: AC220-A-U202 Start Date*: Information not available in EudraCT
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, a...
    Medical condition: Relapsed or Refractory acute myeloid leukemia (AML) in subjects aged ≥1 month to ≤21 years with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutations following failure of fr...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    20.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    20.1 10022891 - Investigations 10076230 Fms-like tyrosine kinase 3 positive PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) FR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004698-15 Sponsor Protocol Number: S60859 Start Date*: 2021-05-03
    Sponsor Name:UZ Leuven / KU Leuven
    Full Title: Brain Injury and Ketamine: a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on Therapy Intensity Level and intracranial pressure in acute brain inju...
    Medical condition: Traumatic Brain Injury patients requiring sedation to control the intracranial pressure (ICP).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001079-22 Sponsor Protocol Number: ABR57022 Start Date*: 2024-07-22
    Sponsor Name:University Medical Center Groningen
    Full Title: A multicenter randomized placebo controlled treatment study of leflunomide in polymyalgia rheumatica
    Medical condition: Polymyalgia Rheumatica
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020992-21 Sponsor Protocol Number: AB06012 Start Date*: 2014-03-25
    Sponsor Name:AB Science
    Full Title: A 24-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 3-parallel groups, Phase 2b/3 study to compare efficacy and safety of masitinib at 3 and 4.5 mg/kg...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004765-40 Sponsor Protocol Number: SPR001-204 Start Date*: 2020-11-17
    Sponsor Name:Spruce Biosciences, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Co...
    Medical condition: Classic Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) LT (Trial now transitioned) LV (Trial now transitioned) IT (Trial now transitioned) EE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000137-37 Sponsor Protocol Number: PALO-03-13 Start Date*: 2005-09-23
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Single Dose, Randomized, Double-Blind, Parallel Group, Multicenter Study of Palonosetron 0.25 mg, 0.50 mg and 0.75 mg Administered by the Oral Route versus Palonosetron 0.25 mg IV for the Preventio...
    Medical condition: Moderately emetogenic chemotherapy induced nausea and vomiting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-003476-39 Sponsor Protocol Number: RG_12-188 Start Date*: 2012-12-04
    Sponsor Name:The University of Birmingham [...]
    1. The University of Birmingham
    2. Manchester University NHS Foundation Trust
    Full Title: Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study.
    Medical condition: Relapsing steroid sensitive nephrotic syndrome
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 25 01:39:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA